The purpose of this study is to compare the incidence hospitalization for severe hypersensitivity and cutaneous reactions among patients with type 2 diabetes who are new users of saxagliptin and those who are new users of other oral antidiabetic drugs.
Prospectively designed retrospective database study. This study will be conducted using administrative claims data and electronic medical records that are collected as part of routine clinical practice
Study Type
OBSERVATIONAL
Enrollment
113,505
Hospitalizations with any hypersensitivity reaction, including anaphylaxis, angioedema, generalized urticaria, SJS, TEN, and other severe skin reactions (i.e., acute generalized exanthematous pustulosis and drug rash with eosinophilia/systemic symptoms)
Time frame: 12-months
Hospitalizations with any hypersensitivity reaction, including anaphylaxis, angioedema, generalized urticaria, SJS, TEN, and other severe skin reactions (i.e., acute generalized exanthematous pustulosis and drug rash with eosinophilia/systemic symptoms)
Time frame: 18-months
Hospitalizations with any hypersensitivity reaction, including anaphylaxis, angioedema, generalized urticaria, SJS, TEN, and other severe skin reactions (i.e., acute generalized exanthematous pustulosis and drug rash with eosinophilia/systemic symptoms)
Time frame: 36-months
Hospitalizations with any hypersensitivity reaction, including anaphylaxis, angioedema, generalized urticaria, SJS, TEN, and other severe skin reactions (i.e., acute generalized exanthematous pustulosis and drug rash with eosinophilia/systemic symptoms)
Time frame: 54-months
Hospitalized for anaphylaxis
Time frame: 12-months
Hospitalized for anaphylaxis
Time frame: 18-months
Hospitalized for anaphylaxis
Time frame: 36-months
Hospitalized for anaphylaxis
Time frame: 54-months
Hospitalized for angioedema
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 12-months
Hospitalized for angioedema
Time frame: 18-months
Hospitalized for angioedema
Time frame: 36-months
Hospitalized for angioedema
Time frame: 54-months
Hospitalized for generalized urticaria
Time frame: 12-months
Hospitalized for generalized urticaria
Time frame: 18-months
Hospitalized for generalized urticaria
Time frame: 36-months
Hospitalized for generalized urticaria
Time frame: 54-months
Hospitalized for severe skin reactions
Time frame: 12-months
Hospitalized for severe skin reactions
Time frame: 18-months
Hospitalized for severe skin reactions
Time frame: 36-months
Hospitalized for severe skin reactions
Time frame: 54-months
Hospitalized for all endpoints
Time frame: 12-months
Hospitalized for all endpoints
Time frame: 18-months
Hospitalized for all endpoints
Time frame: 36-months
Hospitalized for all endpoints
Time frame: 54-months
Hospitalized/emergency room (ER) visits for hypersensitivity reactions
Time frame: 12-months
Hospitalized/emergency room (ER) visits for hypersensitivity reactions
Time frame: 18-months
Hospitalized/emergency room (ER) visits for hypersensitivity reactions
Time frame: 36-months
Hospitalized/emergency room (ER) visits for hypersensitivity reactions
Time frame: 54-months
Death from hypersensitivity reactions
Time frame: 12-months
Death from hypersensitivity reactions
Time frame: 18-months
Death from hypersensitivity reactions
Time frame: 36-months
Death from hypersensitivity reactions
Time frame: 54-months
Hospitalized for Stevens-Johnson syndrome (SJS)
Time frame: 12-months
Hospitalized for Stevens-Johnson syndrome (SJS)
Time frame: 18-months
Hospitalized for Stevens-Johnson syndrome (SJS)
Time frame: 36-months
Hospitalized for Stevens-Johnson syndrome (SJS)
Time frame: 54-months
Hospitalized for for toxic epidermal necrolysis (TEN)
Time frame: 12-months
Hospitalized for for toxic epidermal necrolysis (TEN)
Time frame: 18-months
Hospitalized for for toxic epidermal necrolysis (TEN)
Time frame: 36-months
Hospitalized for for toxic epidermal necrolysis (TEN)
Time frame: 54-months